Freeline Therapeutics Holdings Probability of Future Stock Price Finishing Under 3.65
| FRLNDelisted Stock | USD 4.31 0.28 6.10% |
Freeline |
Freeline Therapeutics Target Price Odds to finish below 3.65
The tendency of Freeline Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to drop to $ 3.65 or more in 90 days |
| 4.31 | 90 days | 3.65 | about 52.54 |
Based on a normal probability distribution, the odds of Freeline Therapeutics to drop to $ 3.65 or more in 90 days from now is about 52.54 (This Freeline Therapeutics Holdings probability density function shows the probability of Freeline Stock to fall within a particular range of prices over 90 days) . Probability of Freeline Therapeutics price to stay between $ 3.65 and its current price of $4.31 at the end of the 90-day period is about 20.18 .
Given the investment horizon of 90 days Freeline Therapeutics Holdings has a beta of -2.29. This usually indicates as returns on its benchmark rise, returns on holding Freeline Therapeutics Holdings are expected to decrease by similarly larger amounts. On the other hand, during market turmoils, Freeline Therapeutics is expected to outperform its benchmark. Additionally Freeline Therapeutics Holdings has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Freeline Therapeutics Price Density |
| Price |
Predictive Modules for Freeline Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Freeline Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Freeline Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Freeline Therapeutics is not an exception. The market had few large corrections towards the Freeline Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Freeline Therapeutics Holdings, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Freeline Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.05 | |
β | Beta against Dow Jones | -2.29 | |
σ | Overall volatility | 1.22 | |
Ir | Information ratio | -0.01 |
Freeline Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Freeline Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Freeline Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Freeline Therapeutics is not yet fully synchronised with the market data | |
| Freeline Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 622 K. Net Loss for the year was (49.93 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Freeline Therapeutics Holdings currently holds about 90 M in cash with (64.24 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.38. |
Freeline Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Freeline Stock often depends not only on the future outlook of the current and potential Freeline Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Freeline Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 4 M | |
| Cash And Short Term Investments | 47.3 M |
Freeline Therapeutics Technical Analysis
Freeline Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Freeline Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Freeline Therapeutics Holdings. In general, you should focus on analyzing Freeline Stock price patterns and their correlations with different microeconomic environments and drivers.
Freeline Therapeutics Predictive Forecast Models
Freeline Therapeutics' time-series forecasting models is one of many Freeline Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Freeline Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Freeline Therapeutics
Checking the ongoing alerts about Freeline Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Freeline Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Freeline Therapeutics is not yet fully synchronised with the market data | |
| Freeline Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 622 K. Net Loss for the year was (49.93 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Freeline Therapeutics Holdings currently holds about 90 M in cash with (64.24 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.38. |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Other Consideration for investing in Freeline Stock
If you are still planning to invest in Freeline Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Freeline Therapeutics' history and understand the potential risks before investing.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |